Lanreotide

Lanreotide (Somatuline Depot) is a real, FDA-approved somatostatin analog for acromegaly and neuroendocrine tumors — the closest direct comparison on this site to octreotide, sharing the same receptor-selectivity profile but delivered as a monthly deep-subcutaneous depot instead.

What it is, and how it compares to octreotide

Lanreotide is a cyclic octapeptide somatostatin analog. Like octreotide, it binds with high affinity almost exclusively to somatostatin receptor subtype 2 (SSTR2), with only moderate affinity for SSTR3/5 and essentially none for SSTR1/4 — the same first-generation receptor-selectivity profile. The practical difference between the two drugs is formulation and dosing interval, not mechanism: lanreotide is delivered as a supersaturated aqueous gel (Depot/Autogel) via deep subcutaneous injection roughly once every 4 weeks (sometimes further extended), versus octreotide's more frequent dosing in its short-acting form or monthly intramuscular depot in its long-acting form.

The approvals and pivotal trials

The FDA first approved lanreotide on 30 August 2007 for acromegaly in patients who haven't responded adequately to surgery or radiotherapy, or for whom those aren't options. A second indication — gastroenteropancreatic neuroendocrine tumors (GEP-NETs) — was added in December 2014, based on the CLARINET trial (Caplin et al., N Engl J Med 2014, PMID 25014687): a 96-week, placebo-controlled trial in 204 patients with metastatic grade 1/2 non-functioning GEP-NETs, which found 24-month progression-free survival of 65.1% with lanreotide versus 33.0% with placebo, with median PFS not reached in the treatment arm versus about 18 months for placebo — a genuinely strong, clean result. A third indication, carcinoid syndrome, was added based on the ELECT trial, which measured reduction in need for rescue octreotide medication rather than survival.

Safety

Safety effects are typical of the somatostatin-analog class: gallstones/gallbladder disease, glucose dysregulation in either direction (hyperglycemia or hypoglycemia), bradycardia and cardiac conduction effects, GI symptoms, injection-site reactions, and potential suppression of other pituitary hormones. No boxed warning.

Current status

Still marketed by Ipsen. A first generic (InvaGen Pharmaceuticals' lanreotide acetate) was FDA-approved 17 December 2021, covering the acromegaly and GEP-NET indications but not, as of that approval, the carcinoid syndrome indication specifically. No FDA warning letter naming lanreotide as a grey-market "research peptide" was found — it has essentially no bodybuilding or cosmetic appeal, unlike the GLP-1 drugs and growth-hormone secretagogues that dominate current FDA peptide-vendor enforcement.